Condition
HER2 Mutation-Related Tumors
Total Trials
5
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
P 1 (4)
P 2 (1)
Trial Status
Recruiting3
Withdrawn2
Clinical Trials (5)
Showing 5 of 5 trials
NCT06253871Phase 1RecruitingPrimary
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06625775Phase 1Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT05868226Phase 1Recruiting
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT04602117Phase 1Withdrawn
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
NCT05041972Phase 2WithdrawnPrimary
ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Showing all 5 trials